– CANADA, Montreal – Thryv Therapeutics Inc. today announced the appointment of Melissa Koomey to its Board of Directors, bringing an impressive depth of experience in product commercialization, launch, and marketing execution.
“We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story. Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa’s experience and insights in Long QT Syndrome. As our earlier portfolio in oncology advances to final stages of preclinical testing, Melissa’s recent commercial launch experience will contribute to our path to commercialization,” ,” said Chairman and CEO, Paul Truex.
Concurrently, Marc-Olivier Sirard will step down from the Board of Directors and transition to a role as Board observer.
About Melissa Koomey
Melissa Koomey has been working for over 30 years in product launch and marketing with leading global pharmaceutical companies across North America, including the last ten years in leadership positions at Gilead Sciences, Inc. Before her current role at Gilead Sciences (Nasdaq: GILD) as VP, Global Commercial Operations, Ms. Koomey was VP and GM for Gilead Canada where she led the growth of Gilead’s new portfolio of cancer therapies and antiviral therapeutics. Previously, Ms. Koomey has held leadership positions across several therapeutic areas with FibroGen, Pfizer, and Novartis. Ms. Koomey holds a Bachelor of Arts from Yale College and a Master of Business Administration from Harvard Business School.
About Thryv Therapeutics Inc.
Thryv Therapeutics Inc. – previously LQT Therapeutics Inc. – is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019, and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers and complement existing therapies.
For more information: https://thryvtrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.